1921
Live-attenuated dengue vaccine development
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Preview this article:
Zoom in
Zoomout

PROGRESS IN DEVELOPMENT OF A LIVE-ATTENUATED, TETRAVALENT DENGUE VIRUS VACCINE BY THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, Page 1 of 1

| /docserver/preview/fulltext/14761645/69/6_suppl/0690001-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690001
2003-12-01
2017-11-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/69/6_suppl/0690001.html?itemId=/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690001&mimeType=html&fmt=ahah

References

  1. Gubler DJ, 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100–103.
  2. Lindback H, Lindback J, Tegnell A, Janzon R, Vene S, Ekdahl K, 2003. Dengue fever in travelers to the tropics, 1998 and 1999. Emerg Infect Dis 9: 438–442.
  3. Siler JF, Hall MW, Hitchens AP, 1926. Dengue, its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J Sci 29: 1–302.
  4. Sabin AB, 1952. Research on dengue during World War II. Am J Trop Med Hyg 1: 30–32.
  5. Deller JJ Jr, Russell PK, 1967. An analysis of fevers of unknown origin in American soldiers in Vietnam. Ann Intern Med 66: 1129–1143.
  6. Trofa AF, DeFraites RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr, 1997. Dengue fever in US military personnel in Haiti. JAMA 277: 1546–1548.
  7. Kanesa-thasan N, Iacono-Connors L, Magill A, Smoak B, Vaughn D, Dubois D, Burrous J, Hoke C, 1994. Dengue serotypes 2 and 3 in US forces in Somalia (letter). Lancet 343: 678.
  8. Sabin AB, Schlesinger RW, 1945. Production of immunity to dengue with virus modified by propagation in mice. Science 101: 640–642.
  9. Wisseman CL Jr, Sweet BH, Rosenzweig EC, Eylar OR, 1963. Attenuated living type 1 dengue caccines. Am J Trop Med Hyg 12: 620–623.
  10. Eckels KH, Brandt WE, Harrison VR, McCown JM, Russell PK, 1976. Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun 14: 1221–1227.
  11. Eckels KH, Harrison VR, Summers PL, Russell PK, 1980. Dengue-2 vaccine: preparation from a small-plaque virus clone. Infect Immun 27: 175–180.
  12. Bancroft WH, Top FH, Eckels KH, Anderson JH, McCown JM, Russell PK, 1981. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 31: 698–703.
  13. Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, Russell PK, 1983. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 148: 1055–1060.
  14. Bancroft WH, Scott RM, Eckels KH, Hoke CH, Simms TE, Jesrani KD, Summers PL, Dubois DR, Tsoulos D, Russell PK, 1984. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 149: 1005–1010.
  15. Eckels KH, Scott RM, Bancroft WH, Brown J, Dubois DR, Summers PL, Russell PK, Halstead SB, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 33: 684–689.
  16. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK, 1987. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 36: 435–442.
  17. Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH, 1988. Virulence of a live dengue virus vaccine candidate: A possible new marker of dengue virus attenuation. J Infect Dis 158: 876–880.
  18. Halstead SB, 1978. Studies on the attenuation of dengue 4. Asian J Infect Dis 2: 112–117.
  19. Halstead SB, Marchette NJ, 2003. Biological properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69 (suppl): (in press).
  20. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A, 1987. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 65: 189–195.
  21. Bhamarapravati N, Yoksan S, 1989. Study of bivalent dengue vaccine in volunteers (letter). Lancet 1: 1077.
  22. Hoke CH Jr, Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, Simms T, Burrous J, Hasty SE, Bancroft WH, 1990. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 43: 219–226.
  23. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH, 1994. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 170: 1448–1455.
  24. Harrison VR, Eckels KH, Sagartz JW, Russell PK, 1977. Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infect Immun 18: 151–156.
  25. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr, 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69 (suppl): (in press).
  26. Kanesa-thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr., 2003. Phase 1 Studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 69 (suppl): (in press).
  27. Sun W, Edelman R, Kanesa-thasan N, Eckels KH, Putnak R, King AD, Huong H-S, Tang D, Scherer JM, Hoke CH Jr, Innis BL, 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 (suppl): (in press).
  28. Edelman R, Wasserman SS, Bodison SA, Putnak JR, Eckels KH, Tang D, Kanesa-thasan N, Vaughn DW, Innis BL, Sun W, 2003. Phase 1 trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (suppl): (in press).
  29. Kanesa-thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R, 2003. Atypical viremia and atypical antibody responses in dengue vaccine recipients with prior yellow fever vaccination. Am J Trop Med Hyg 69 (suppl): (in press).
  30. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, Delgado I, Halstead SB, 2000. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152: 793–799.
  31. Gwinn W, Sun W, Innis BL, Caudill J, King AD, 2003. Serotype-specific Th1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg 69 (suppl): (in press).
  32. Rothman AL, Ennis F, 1999. Immunopathogenesis of dengue hemorrhagic fever. Virology 257: 1–6.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2003.69.6_suppl.0690001
Loading

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error